Results overview: Found 2 records in 0.01 seconds.
Articles, 1 records found
Research literature, 1 records found
Articles 1 records found  
1.
20 p, 10.3 MB PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines / Ginés Molina, Alba (Institut Germans Trias i Pujol) ; Bystrup, Sara (Institut Germans Trias i Pujol) ; Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol) ; Guardia, Cristina (Institut Germans Trias i Pujol) ; Musulén Palet, Eva (Institut Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol) ; Manzano, José Luis (Institut Germans Trias i Pujol) ; Layos, Laura (Institut Germans Trias i Pujol) ; Abad, Albert (Institut Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and also in patients. [...]
2015 - 10.1371/journal.pone.0123830
PloS one, Vol. 10, No. 5 (May 2015) , p. e0123830  

Research literature 1 records found  
1.
235 p, 3.3 MB Estudi del paper de la isoforma M2 de Piruvat Quinasa (PKM2) en la resposta i resistència a oxaliplatí en línies cel·lulars i en pacients amb càncer colorectal avançat / Ginés Molina, Alba ; Martínez Balibrea, Eva, dir. (Institut Català d'Oncologia) ; Abad, Albert, dir. (Institut Català d'Oncologia) ; Universitat Autònoma de Barcelona. Departament de Medicina
Colorectal cancer is the second most common cause of cancer death in the world and the most frequent tumor in Spain including both genders. Survival of the advanced disease has increased from 12 months with monotherapy to roughly 2 years with the addition of cytotoxic and cytostatic drugs combined with targeted drugs. [...]
El càncer colorectal és la segona causa de mort per càncer al món i el tumor més freqüent a l'Estat Espanyol englobant ambdós sexes. El tractament de la malaltia avançada es basa en la combinació de fàrmacs citotòxics, citostàtics i noves molècules anti-diana, assolint-se medianes de supervivència al voltant dels 2 anys. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2013  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.